BeOne Medicines (NASDAQ:ONC) Insider Titus Ball Sells 132 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Titus Ball sold 132 shares of the firm’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $355.86, for a total transaction of $46,973.52. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

BeOne Medicines Stock Up 0.2%

Shares of ONC opened at $362.68 on Friday. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $253.95 and a 52 week high of $385.22. The firm has a market cap of $39.82 billion, a P/E ratio of 63.85 and a beta of 0.51. The firm’s 50-day simple moving average is $332.38 and its 200 day simple moving average is $311.36. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings results on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.65. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The firm had revenue of $1.71 billion for the quarter, compared to analysts’ expectations of $1.66 billion. On average, analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 8.81 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. Morgan Stanley reissued an “overweight” rating on shares of BeOne Medicines in a report on Thursday, August 6th. Citizens Jmp lifted their price objective on shares of BeOne Medicines from $396.00 to $405.00 and gave the stock a “market outperform” rating in a research note on Thursday, August 6th. Leerink Partners increased their target price on shares of BeOne Medicines from $364.00 to $367.00 and gave the stock an “outperform” rating in a research report on Friday, May 15th. Nomura raised shares of BeOne Medicines to a “strong-buy” rating in a report on Monday, July 27th. Finally, Guggenheim boosted their price target on BeOne Medicines from $420.00 to $430.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $402.14.

Institutional Investors Weigh In On BeOne Medicines

A number of large investors have recently bought and sold shares of ONC. EFG International AG acquired a new position in shares of BeOne Medicines in the 4th quarter valued at approximately $25,000. Leonteq Securities AG bought a new position in BeOne Medicines in the fourth quarter valued at approximately $35,000. Daiwa Securities Group Inc. acquired a new position in BeOne Medicines during the second quarter valued at approximately $35,000. CWM LLC lifted its stake in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company’s stock worth $48,000 after purchasing an additional 39 shares during the last quarter. Finally, Group One Trading LLC bought a new stake in BeOne Medicines during the fourth quarter worth $61,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.